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Background: Pneumococcal pneumonia is a leading cause of childhood mortality. Pneumococcal conjugate 
vaccines (PCVs) have been shown to reduce hypoxic pneumonia in children. However, there are no studies 
from Asia examining the effectiveness of PCVs on hypoxic pneumonia. We describe a novel approach 
to determine the effectiveness of the 13-valent PCV (PCV13) against hypoxia in children admitted with 
pneumonia in the Lao People’s Democratic Republic. 
Methods: A prospective hospital-based, test-negative observational study of children aged up to 59 
months admitted with pneumonia to a single tertiary hospital in Vientiane was undertaken over 54 
months. Pneumonia was defined using the 2013 WHO definition. Hypoxia was defined as oxygen satu- 
ration < 90% in room air or requiring oxygen supplementation during hospitalisation. Test-negative cases 
and controls were children with hypoxic and non-hypoxic pneumonia, respectively. PCV13 status was 
determined by written record. Vaccine effectiveness was calculated using logistic regression. Propensity 
score and multiple imputation analyses were used to handle confounding and missing data. 
Findings: There were 826 children admitted with pneumonia, 285 had hypoxic pneumonia and 377 were 
PCV13-vaccinated. The unadjusted, propensity-score adjusted and multiple-imputation adjusted estimates 
of vaccine effectiveness against hypoxic pneumonia were 23% (95% confidence interval: -9, 46%; p = 0 • 14); 
37% (6, 57%; p = 0 • 02) and 35% (7, 55%; p = 0 • 02) respectively. 
Interpretation: PCV13 is effective against hypoxic pneumonia in Asia, and should be prioritised for inclu- 
sion in national immunisation programs. This single hospital-based, test-negative approach can be used 
to assess vaccine effectiveness in other similar settings. 
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l  Research in context 
Evidence before this study 
We searched Medline (Ovid), Embase (Ovid) and Pubmed 
for reports published before January 2019 for terms: pneu- 
mococcal conjugate vaccine, pneumonia, pneumo ∗, Strepto- 
coccus pneumoniae . We searched for studies that evaluated 
the vaccine efficacy and vaccine effectiveness (VE) of the 
13-valent pneumococcal conjugate vaccine (PCV13) against 
outcomes of hypoxic pneumonia and mortality attributable 
to pneumonia. The population of interest was children un- 
der five years of age, using either randomised control trials 
(RCTs), observational population-based or case-control stud- 
ies. We identified six studies assessing PCV VE against pneu- 
monia mortality. This included four observational studies that 
reported a PCV VE between 8-71% against pneumonia-related 
mortality. Additionally, one RCT was identified, which re- 
ported a 54% reduction in mortality attributable to pneumo- 
nia (p = 0 • 73). We identified two observational studies that 
found a 47-61% reduction in hypoxic pneumonia post PCV13 
introduction. All studies were in Europe, Africa and South 
America. There are no published studies on the PCV13 VE 
against pneumonia or hypoxic pneumonia in Asia, and no 
studies using a single hospital-based approach. 
Added value of this study 
We conducted a prospective observational study in a sin- 
gle hospital to determine the PCV13 VE against hypoxic pneu- 
monia and pneumonia requiring supplementary oxygen in 
children compared to non-hypoxic children with pneumonia 
in the Lao People’s Democratic Republic (Lao PDR, Laos) be- 
tween December 2013 and June 2018. We found that PCV13 
reduced hypoxic pneumonia and pneumonia requiring sup- 
plementary oxygen by 37% ( 95% confidence interval: 6, 57%; 
p = 0 • 02) in children with pneumonia. This is the first study 
documenting the impact of PCV13 on hypoxic pneumonia in 
Asia. We outline a novel method using a test-negative design 
to determine the VE using a single hospital approach. 
Implications of all the available evidence 
The WHO recommends that evaluation of the impact of 
PCVs on pneumococcal diseases should be undertaken to in- 
form vaccine policy decisions. However, in LMICs, population- 
level surveillance data may not be available, and undertak- 
ing large-scale epidemiological studies is expensive and time 
consuming. In these settings, case-control studies may be 
utilised to measure VE. However, case-control studies may be 
vulnerable to confounding and other challenges in the selec- 
tion of appropriate controls. Previously, Madhi et al noted in 
their case-control study evaluating the VE of PCV7 and PCV13 
against presumed bacterial pneumonia, confirmed radiologi- 
cally, that hospital controls were more comparable to cases 
than community controls in regards to demographic data. In 
our study, we outline a novel method using a test-negative 
design that can be conducted within a single hospital. This is 
a simple methodological approach, which can be utilised in 
other settings. Our study is the first to report on the VE of 
PCV13 in Asia. Asian countries have been very slow to intro- 
duce PCV into their national immunisation programs. These 
results provide supportive evidence for decision-makers in 
other countries, particularly LMICs, to include PCV into their 
national programs. PCV13 is particularly effective against the 
most severe form of pneumonia (hypoxic pneumonia), which 
is consistent with other studies. As hypoxia is the precursor 
to mortality, our results suggest that PCV13 will contribute to 
a reduction in childhood mortality in Laos and more broadly 
in the region, providing evidence of impact to support the 
continued use of PCV13 in Laos. . Introduction 
Globally, lower respiratory infections, including pneumonia, are
 leading cause of morbidity and mortality in children under five
ears old, causing 652,572 deaths annually [1] , predominantly in
ow- and middle-income countries (LMICs) [2] . Streptococcus pneu-
oniae (pneumococcus) is estimated to cause over half of all
neumonia-related deaths in children under five years old [1] .
here are more than 90 different pneumococcal serotypes, but
nowledge is limited of their relative contribution to disease and
heir geographic and demographic variation [3] . 
This high burden of disease prompted the development of the
nfant pneumococcal conjugate vaccines (PCVs), including the 13-
alent PCV (PCV13), which covers 13 of the most common disease-
ausing pneumococcal serotypes. In randomised controlled trials
RCTs), the efficacy of PCV against radiologically-confirmed child-
ood pneumonia ranges from 20-37% [ 4 , 5 ]. One RCT found a 16%
95% confidence interval [CI]: 3, 28%) reduction of all-cause mor-
ality in children under two years old [4] . Observational studies
ave found an 8-71% reduction in pneumonia-related mortality in
hildren aged under two years old following the introduction of
CV [6–8] . One study noted a greater decline in pneumonia-related
ortality in lower socioeconomic groups (10% v 24%) [8] . No RCTs
ave assessed vaccine efficacy against hypoxic pneumonia, a pre-
ursor of mortality. There are only two observational studies from
frica, which reported 47% and 61% reductions in hypoxic pneumo-
ia in children under five years old following PCV13 introduction
 9 , 10 ]. No studies have assessed the impact of the currently avail-
ble PCVs against any pneumonia endpoint in Asian LMICs [ 11 , 12 ].
As PCVs are expensive, governments require evidence of their
ealth benefits within their populations. However, measuring the
mpact or effectiveness of PCVs is challenging. To document PCV
mpact on pneumonia, countries often rely on routinely collected
dministrative data on hospitalisations, which may not be com-
lete, as well as population denominators, which are often not
vailable. Vaccine effectiveness (VE) is commonly measured us-
ng cohort or case-control studies. Cohort studies require follow-
p of vaccinated and unvaccinated participants for the occurrence
f study endpoints, which can be expensive and difficult to im-
lement in low-resource settings [13] . Measuring VE using the
tandard case-control design is challenging due to difficulties in
electing controls that are representative of the source popula-
ion of the cases [13] . In particular, biases can arise due to dif-
erences in health-seeking behaviour of the cases and controls
14] . Test-negative studies, a variant of case-control studies, have
een proposed as an alternative approach for estimating VE [14] .
ith the test-negative design, cases and controls present with the
ame clinical syndrome, but differ with respect to their test result
or a disease or pathogen of interest [15] . Because the cases and
ontrols present to health facilities with similar signs and symp-
oms, they are likely to come from the same catchment areas and
ave comparable health-seeking behaviour and data quality [15] .
est-negative studies can also provide practical advantages as they
an be carried out within a single hospital or surveillance system
13] . Similar approaches (e.g. “Broome method” [16] , “indirect co-
ort” method [17] ) have been used to examine the effectiveness
f PCVs against vaccine-type invasive pneumococcal disease in set-
ings where diagnostic testing is available. 
Pneumonia is a leading cause of infant mortality in the Lao Peo-
le’s Democratic Republic (Laos) [18] . Universal health care did not
xist in Laos until recently, and supplementary oxygen was pro-
ibitively expensive for families [19] . As such, the PCV13 has great
otential to alleviate this burden of disease on the most vulner-
ble. In October 2013, Laos introduced PCV13 into the national
hildhood vaccination program, supported by Gavi, the Vaccine Al-
iance. As the country is undergoing Gavi transition, the Ministry of
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b  ealth requested evidence of the health benefits of PCV to support
ts ongoing use. The vaccine is administered in a “3 + 0” schedule
t six, ten, and 14 weeks of age, and during the initial roll-out,
atch-up vaccination was offered to infants up to 12 months old.
n this study, we aimed to determine the effectiveness of PCV13 on
ypoxic pneumonia in children in Laos, using a prospective single-
ospital approach. We use a novel approach that enrols all chil-
ren with pneumonia, and defines “test-negative” cases and con-
rols as hypoxic and non-hypoxic pneumonia patients, respectively.
his is a modified approach to the “test-negative” design, which
sually defines case and control status based upon test results for
 pathogen [14] . 
. Methods 
.1. Study site 
This study was conducted at Mahosot Hospital in Vientiane, the
apital of Laos. It is a 365-bed general tertiary referral hospital and
rimary care provider to the local catchment area. Approximately
00 children less than five years old are admitted with acute respi-
atory infections (ARIs) each year. Respiratory infection admissions
re known to peak in the hot rainy season in Laos. Oxygen sup-
lementation was available for this study at no cost to the patient
nd their families. In 2016, the national coverage of the third dose
f PCV13 was estimated to be 78% [20] . 
.2. Study design 
This was a prospective hospital-based study of children admit-
ed with an ARI to any paediatric or intensive care ward at Ma-
osot Hospital, nested within ongoing hospitalised ARI surveillance
21] . The test-negative analysis included pneumonia cases enrolled
rom December 2013 to July 2018 (when the planned sample size
as attained, see “Sample size calculation” section). Six cases (n = 1
ypoxic, n = 4 not hypoxic, n = 1 unrecorded oxygen saturation) en-
olled in December 2013 were classified as 2014 cases for analyses
sing year of enrolment. 
.3. Study participants 
Children were enrolled into the ARI surveillance if they were
ged 0-59 months and admitted with a primary diagnosis of
RI defined as: ≤14-day history of fever or documented fever
 > 38 • 0 °C, axillary, rectal or oral), and one or more of: cough; rhini-
is; dyspnoea or abnormal auscultatory findings (reduced breath
ounds or inspiratory crepitations). Only children who fulfilled
he definition of pneumonia, i.e. children with cough or difficulty
reathing, and one of either tachypnoea ( ≥60 breaths per minute
bpm) < 2 months old; ≥50 bpm if 2-11 months old; or ≥40 bpm
f 12-59 months old) or chest indrawing, were included [22] . Chil-
ren were excluded if their parents did not consent or they did not
t the clinical definition of pneumonia. 
.4. Study procedures 
Study staff screened potential recruits from Monday to Friday
ach week. For those eligible, following written, informed con-
ent from parents/guardians, information on demographics, med-
cal history and clinical details were collected through parental
nterview and review of the medical records, and recorded on a
ata collection form by study staff. The data collected included:
ate of enrolment; season of enrolment (Wet (May to September)
r Dry (October to April)); number of other people living in the
ousehold; source of cooking fuel (electricity, coal, wood or gas);
hether the household had piped water; ethnicity of the family;esidence (within Vientiane Capital or other provinces); comor-
idities (concurrent infection, malnutrition, congenital heart dis-
ase, chronic lung disease, cancer, asthma, diabetes, prematurity or
ow birth weight); required assisted ventilation (continuous pos-
tive airway pressure (CPAP) or mechanical ventilation); intensive
are admission for > 24 hours; outcome (death, discharged alive);
nd attendance at day-care centre. Each participant had a nasopha-
yngeal swab taken, which was tested for pneumococcus and hu-
an respiratory syncytial virus (HRSV) (See Supplementary meth-
ds for details). The pneumococcal and HRSV results were used
s a control condition and confounder in this study, respectively.
CV13 vaccination status was recorded from the parent-held im-
unisation record or health centre immunisation records. 
.5. Study measures 
The primary outcome was hypoxia, defined as an oxygen satu-
ation of < 90% in room air on admission or requiring oxygen sup-
lementation during admission. Oxygen saturation was recorded
sing the non-invasive Masimo® and Lifebox® oximeters. For the
est-negative design, cases were defined as children who met the
ase definition for pneumonia and were hypoxic. Because oxy-
en saturations were only recorded on admission, we additionally
onsidered participants to be cases if they required oxygen sup-
lementation during their hospitalisation. Test-negative controls 
ere children with non-hypoxic pneumonia. Children were con-
idered PCV13-vaccinated if they had received at least two doses of
CV13 and were aged between 0-11 months; and for those children
lder than 12 months, if they had received at least one dose of
CV13 [23] . Children were considered undervaccinated if they had
eceived fewer doses by age group. 
.6. Data management 
Data collection forms of all participants were reviewed and up-
oaded into a REDCap database hosted at the Murdoch Children’s
esearch Institute [ 24 , 25 ]. Data were monitored, corrected then
ouble-entered. 
.7. Statistical analysis 
Categorical data were summarised as numbers and percentages.
ontinuous data were summarised as medians and interquartile
anges. Age was reported as both a continuous and categorical
ariable. 
Logistic regression was used to estimate the odds ratios (OR)
nd associated 95% CI of hypoxic pneumonia by PCV13 vaccination
tatus. The ORs were converted to measures of VE using the for-
ula: VE = (1-OR) ∗100. To handle potential confounding, we used
nverse probability of treatment weighting (IPTW), which weights
ndividuals by the inverse of the probability of PCV13 vaccination
onditional on covariates (i.e. the propensity score (PS)). The PS
as estimated using a logistic regression model with PCV13 sta-
us as the outcome variable and potential confounders as covari-
tes. The following variables were included in the propensity score
odel based on prior subject matter knowledge: age, sex, sea-
on, day care attendance, number of other people in the house-
old, comorbidities, date of enrolment, and HRSV infection status.
 number of additional variables (maternal education, access to
iped water, cooking fuel, ethnicity, and residence in a rural or ur-
an setting) were included in the model based on observed differ-
nces between the vaccinated and undervaccinated groups. To as-
ess balance of covariates between vaccinated and undervaccinated
roups, we calculated standardised differences for each covariate
efore and after weighting. Covariates were considered balanced
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Eligible
(n=1799)
Enrolled 
(n=1375)
Pneumonia cases
(n=826)
Hypoxic pneumonia and pneumonia
requiring oxygen supplementation2
(n=285)
Screened
(n=4,812)
Declined consent
(n=133)
PCV13 
undervaccinated 
(n=114)
PCV13 
vaccinated
(n=115)
PCV13 status
unknown
(n=56)
Missed1
(n=291)
Unknown oxygen status
(n=32)
PCV13 status
unknown
(n=14)
PCV13 status
unknown
(n=14)
PCV13 status
unknown
(n=4)
Pneumonia cases that were not hypoxic
or requiring oxygen supplementation
(n=509)
PCV13 
undervaccinated 
(n=177)
PCV13 
vaccinated
(n=248)
PCV13 
status unknown
(n=84)
Fig. 1. Flow chart of study recruitment of children of children with pneumonia between the age of 0-59 months at the Mahosot Hospital, Vientiane, Lao PDR between 
December 2013 and July 2018 (n = 4,312). 
Legend: 1 Missed cases refer to cases not enrolled due to admission and discharge over the weekend. 2 Hypoxic pneumonia and pneumonia requiring oxygen supplementation 
includes any cases with hypoxic oxygen saturation levels ( < 90% O 2 ) measured (at any stage during admission) and those cases receiving oxygen supplementation at any 
stage during admission. 
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pif the weighted standardised differences were < 10% [26] . We per-
formed an additional analysis using similar methods to estimate
PCV13 VE against a control condition of total pneumococcal car-
riage (defined as the carriage of any pneumococcal serotype, as
measured by the analysis of nasopharyngeal swabs as described in
the Supplementary methods). Total pneumococcal carriage was se-
lected as a control condition, as we do not expect PCV13 to affect
overall pneumococcal carriage rates [27] . 
Some children had unknown PCV13 vaccination status and un-
recorded oxygen saturation levels. To assess for systematic differ-
ences between children with and without missing values, we com-
pared them on demographic and medical characteristics and as-
sessed differences using Chi-squared tests for categorical variables
and Wilcoxon rank-sum tests for continuous variables. Primary VE
analyses included participants with completely observed data on
all variables in the adjusted and unadjusted analyses (i.e. complete
case analyses). We examined the sensitivity of the results to the
handling of missing data by using multiple imputation (See Sup-
plementary methods). The missing data were imputed using mul-
tiple imputation by chain equations (MICE) using the mi impute
chained command in Stata, with 40 imputed datasets created. The
unadjusted and PS analyses were performed separately on each
imputed dataset, and the results combined using Rubin’s rules [28] .
Data cleaning and analysis were conducted using Stata version 15
[29] . 
2.8. Sample size calculation 
It was estimated that the PCV13 VE against hypoxic pneumonia
was 40% based upon a published study [10] . Assuming 60% of con-
trols were vaccinated and a 2:1 ratio of controls to cases, a sampleize of 256 cases and 511 controls would have 90% power to detect
n odds ratio of 0.6 (i.e. VE of 40%). 
.9. Ethics approval 
This study was conducted according to the study protocol ap-
roved by the Oxford Tropical Research Ethics Committee (Ox-
REC reference:1050-13), Laos Ministry of Health National Ethics
ommittee for Health Research (No 061NECHR), the Ethics Review
ommittee of the WHO Regional Office for the Western Pacific Re-
ion (WPRO-ERC) (reference ID:2013.30.LAO.2.EPI) and The Royal
hildren’s Hospital Human Resources Ethics Committee (HREC)
reference number:33177B). 
.10. Role of the funding source 
This work was supported by the Bill & Melinda Gates Foun-
ation (OPP1115490) with additional support from the Wellcome
rust. The funders had no role in the study design, data collection,
ata analysis, data interpretation, or writing of the report. The cor-
esponding author had full access to all data in the study and had
nal responsibility for the decision to submit for publication. 
. Results 
Between December 2013 to July 2018, 4,812 children were
creened ( Fig. 1 ). There were 1,375 children enrolled in the study
or whom consent was given. Of these, 826 children had pneumo-
ia and 96 • 1% had oxygen saturation recorded. PCV13 vaccination
tatus was confirmed by written record for 82 • 6% of children with
neumonia. 
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Table 1 
Characteristics of children admitted with pneumonia, by hypoxic pneumonia v non-hypoxic pneumonia status (n = 826). 
Characteristics Total (n = 826) 
Hypoxic pneumonia 
(n = 285) 
Non-hypoxic pneumonia 
(n = 509) p-value 
Age in months, median (IQR) 11.4 (4 • 6-19 • 9) 8 • 0 (2 • 8-15 • 9) 13 • 2 (5 • 7-21 • 4) < 0 • 001 
Age < 12 months, n (%) 430 (52.1) 183 (64 • 2) 236 (46 • 4) < 0 • 001 
Female, n (%) 349 (42 • 3) 125 (43.9) 211 (41.5) 0 • 51 
Ethnicity (Lao Loum), n (%) 717 (86 • 8) 238 (83 • 5) 451 (88 • 6) 0 • 042 
PCV13 status 1 , n/N (%) 
Vaccinated 377/682 (55.3) 115/229 (50.2) 248/425 (58 • 4) 0 • 046 
Undervaccinated 305/682 (44.7) 114/229 (49 • 8) 177/425 (41 • 7) 
Comorbidities 2 , n (%) 97 (11 • 7) 53 (18 • 6) 43 (8 • 4) < 0 • 001 
HRSV positive, n/N (%) 257/767 (33 • 5) 83/261 (31 • 8) 168/474 (35 • 4) 0 • 32 
Urban residence (Vientiane capital district), n (%) 655 (79 • 3) 203 (71 • 2) 428 (84 • 1) < 0 • 001 
Daycare attendance 3 , n/N (%) 105/822 (12 • 8) 20/284 (7 • 0) 81/507 (16 • 0) < 0 • 001 
Mother’s level of education higher than junior high school, n/N (%) 564/733 (76 • 9) 183/250 (73 • 2) 358/451 (79 • 4) 0 • 06 
Wet season 4 , n (%) 373 (45 • 2) 121 (42 • 5) 240 (47 • 2) 0 • 20 
Year of enrolment 5 , n (%) 
2014 254 (30 • 7) 76 (26 • 7) 165 (32 • 4) 0 • 005 
2015 198 (24 • 0) 55 (19 • 3) 128 (25 • 1) 
2016 185 (22 • 4) 83 (29 • 1) 99 (19 • 4) 
2017 144 (17 • 4) 50 (17 • 5) 94 (18 • 5) 
2018 45 (5 • 4) 21 (7 • 4) 23 (4 • 5) 
Number of other people in household, median (IQR) 5 (4-7) 5 (4-7) 5 (4-7) 0 • 41 
Piped water source 6 , n (%) 431 (52 • 2) 125 (43 • 9) 289 (56 • 8) < 0 • 001 
Wood used for cooking 7 , n (%) 345 (41 • 8) 142 (49 • 8) 192 (37 • 7) < 0 • 001 
Supplementary oxygen used, n (%) 256 (31.0) 256 (89.8) 0 (0) < 0.001 
Assisted ventilation 8 , n/N (%) 26/824 (3.2) 25/284 (8.8) 1/508 (0.2) < 0.001 
Wheeze, n/N (%) 297/661 (44.9) 102/234 (43.6) 195/427 (45.7) 0.61 
Death, n (%) 9 (1.1) 9 (3.1) 0 (0) < 0.001 
Legend: IQR: interquartile range. For categorical variables, data are presented as frequencies (n), or fractions (n/N) for variables with missing data. 
1 PCV 13 status: 0-11 months 2 doses of PCV13; > 12 months 1 dose; undervaccinated: ≤11 months 0-1 dose; ≥12 months 0 doses of PCV13. 
2 Comorbidities included: concurrent infection, malnutrition, congenital heart disease, chronic lung disease, cancer, asthma, diabetes, prematurity or low birth 
weight. 
3 Attendance at daycare indicates children attended daycare for any length of time. 
4 Season: wet season refers to period between May to September, dry season refers to period between October to April. 
5 Year of enrolment refers to enrolment in study from 1 st of January to 31 st of December of that year (2013 was merged with 2014 due to low numbers), 
except 2017 which was January to June. 
6 Piped water source: Household had piped water supply. 
7 Wood used for cooking: Household had wood as primary cooking fuel as opposed to other sources. 
8 Assisted ventilation: CPAP or mechanical ventilation. 
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aThe median age of the participants with pneumonia (n = 826)
as 11 months (IQR:4 • 6-19 • 9) and 52.1% were infants (under 12
onths) ( Table 1 ). Of the children with pneumonia, 55.3% were
CV13-vaccinated, 35.9% were hypoxic, 31 • 0% received supplemen-
ary oxygen and 33 • 5% were HRSV positive. In total, 11 • 7% of chil-
ren had a comorbidity. Of the 285 participants who were clas-
ified as cases, 139 (49%) had an oxygen saturation of < 90% in
oom air on admission, and 146 (51%) were not hypoxic on admis-
ion, but required supplementary oxygen during their hospitalisa-
ion. There were only minor differences between these two groups;
hose who were hypoxic on admission were less likely to reside
n homes that used wood for cooking (43% v 56%), less likely to
e admitted during the wet season (35% v 49%), and more likely
o be enrolled earlier in the study (e.g. 53% v 39% enrolled before
016) compared to those who were non-hypoxic on admission but
equired supplementary oxygen (Supplementary Table 1). 
Characteristics of children with and without hypoxic pneumo-
ia are shown in Table 1 . Children with hypoxic pneumonia were
ounger (median age: 8 months v 13 months), were less likely to
ome from homes with piped water (44% v 57%), were less likely
o live in Vientiane Capital (71% v 84%), were less likely to attend
aycare (7% v 16%) and were less likely to be of Lao Loum ethnicity
84% v 89%) compared to non-hypoxic children ( Table 1 ). Children
ith hypoxic pneumonia were also more likely to reside in homes
hat used wood for cooking (50% v 38%) and more likely to have a
omorbidity (19% v 8%). 
Of the 826 pneumonia patients, 144 (17 • 4%) had missing PCV13
accination status, 36 (4 • 4%) had unrecorded oxygen saturation
evels and 570 (69%) had complete data for all variables in theropensity score analysis. Compared to children with known PCV13
tatus, those with unknown PCV13 status were enrolled later in the
tudy (e.g. 60% v 42% enrolled after 2015), more likely to reside in
omes that used wood for cooking (55% v 39%), less likely to live
n a home with piped water (40% v 55%,), less likely to live in Vien-
iane Capital (62% v 83%) and less likely to be of Lao Loum ethnic-
ty (77% v 89%) (Supplementary Table 2). Children with unrecorded
xygen saturations were enrolled earlier in the study compared to
hose with recorded levels (e.g. 86% vs 53% enrolled before 2016)
Supplementary Table 3). 
There were also differences between vaccinated and undervac-
inated children (Supplementary Table 4). Among participants with
ompletely observed data (n = 570), undervaccinated children were
ounger (median age: 6 months v 13 months) and enrolled ear-
ier in the study (e.g. 51% v 24% enrolled before 2015) compared to
accinated children. Vaccinated children were more likely to come
rom homes with maternal education levels higher than primary
84% v 73%) and homes with piped water (63% v 43%). Following PS
eighting, standardised differences between covariates were < 10%,
ndicating that covariates were balanced between exposure groups
Supplementary Table 4). 
The unadjusted VE against hypoxic pneumonia was 23% (95%
I: -9, 46%; p = 0 • 14) ( Table 2 ). When adjusted for confounders us-
ng PS analysis the VE was 37% (95% CI: 6, 57%; p = 0 • 02) ( Table 2 ).
he unadjusted and PS-adjusted VE using multiple imputation
ere: 31% (95% CI: 6, 50%; p = 0 • 02) and 35% (95% CI: 7, 55%;
 = 0 • 02) respectively ( Table 2 ). The VE against total pneumococ-
al carriage was -6% (95% CI: -54, 28%; p = 0.78) in the PS-adjusted
nalysis of the control condition (Supplementary Table 5). 
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Table 2 
Unadjusted and propensity score adjusted PCV13 vaccine effectiveness (VE) against hypoxic pneu- 
monia 1 . Results are shown for complete case analyses (n = 570) and multiple imputation analyses 
(n = 826). 
Unadjusted PCV13 
VE (95% CI) 
p-value Adjusted PCV13 VE 
(PS 2 ) (95% CI) 
p-value 
Complete case analysis 23 (-9, 46) 0 • 14 37 (6, 57) 0 • 02 
Multiple imputation 31 (6, 50) 0 • 02 35 (7, 55) 0 • 02 
Legend: 
1 Hypoxic pneumonia (Oxygen saturation (1st measured) either at or during admission: non- 
hypoxic: ≥90% O 2 and hypoxic < 90%) and cases requiring oxygen supplementation therapy at any 
stage during admission. 
2 PS (Propensity score): individuals were weighted by the inverse probability of the conditional 
likelihood of being vaccinated using logistic regression on covariates: age, sex, season, day care at- 
tendance, number of adults in the household, maternal education, access to piped water, cooking 
fuel, ethnicity, date of enrolment, residing in a rural or urban setting, comorbidities and HRSV in- 
fection status. 
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d  4. Discussion 
Using a novel single hospital-based test-negative study design,
this is the first study to show that PCV13 is effective against hy-
poxic pneumonia in Asian children. Considering the high burden
of pneumonia and limited access to treatment in these settings,
PCV13 is likely to substantially reduce childhood mortality. Most
countries in Asia do not include PCV in their national immunisa-
tion programs. Our findings suggest that PCV should be considered
a priority for introduction in Asia, especially for children most at
risk of pneumonia and in countries with high child mortality. 
Our results are consistent with two other observational stud-
ies of PCV13 from Africa, which both found reductions in hypoxic
pneumonia in children [ 9 , 10 ]. In Malawi, there was a 47% (95% CI:
5%, 70%, p = 0.031) reduction in hypoxic pneumonia post-PCV13
introduction [9] . In The Gambia, there was a 61% (95% CI: 52%,
68%) reduction in the incidence of hypoxic pneumonia post-PCV13
introduction [10] . Our study in Laos found a 37% reduction in hy-
poxic pneumonia (when adjusted for confounders). Differences in
reported effect sizes may be due to a variety of factors, including
geographic variation in pneumococcal serotypes that cause pneu-
monia. There were numerous differences in the study designs: the
Malawi study used a time series analysis of pneumonia surveil-
lance data, and the Gambian study compared incidences of hypoxic
pneumonia in pre- and post-PCV13 periods using surveillance data,
while our study used a PS analysis to estimate VE using cases
enrolled in surveillance at a single hospital. All studies included
children under the age of five years. However, the Gambian study
limited their study to children over the age of two months. The
study populations likely differed in demographic factors, comor-
bidities and other risk factors which may influence the severity of
illness or health seeking behaviour [2] . All three studies investi-
gated a “3 + 0” vaccination schedule with catch up. However, The
Gambia achieved higher PCV13 population coverage (96%) com-
pared with Malawi (76%) and our site (78%) [ 9 , 10 , 20 ]. Although it
is unknown what coverage is required to confer herd protection
[30] , the higher coverage in The Gambia along with longer follow
up time may have resulted in greater herd protection and thereby
higher vaccine impact. The advantage of the observational vaccine
impact study design is that it may capture these indirect effects
[31] . 
No RCTs have used hypoxic pneumonia or mortality due to
pneumonia as a primary outcome for PCV vaccine efficacy. How-
ever, a meta-analysis of RCTs reported smaller, but comparable,
PCV effect sizes against all-cause mortality (11%; [95% CI] -1%,
21%, p = 0.08) and radiologically-confirmed pneumonia (27%; [95%
CI] 15%, 36%, p < 0.0 0 01) to our study’s findings [5] . This differ-
ence may reflect the greater specificity of hypoxic pneumonia as
an outcome, and thus provide a more accurate assessment of effectize. The outcome of hypoxic pneumonia was used in this study
s it is a marker of severe pneumonia, is a precursor to mortality,
nd it is relatively easy to measure [32] . The WHO clinical pneu-
onia definition is sensitive but has low specificity for pneumo-
occal pneumonia. Studies have found the vaccine effectiveness of
CV against clinical pneumonia to be lower than for more specific
neumonia definitions, such as radiologically-confirmed pneumo-
ia, and therefore larger samples are required to show any effect
22] . Additionally, we included pneumonia cases requiring oxygen
upplementation in the outcome measure, as oxygen saturations
ere only recorded on admission. Therefore, using only “hypoxia”
ould not have captured the cases who deteriorated clinically dur-
ng their hospitalisation. 
This is the first study to describe this single-hospital approach
o measure VE and provides a simple and feasible approach for
ther LMICs to adopt. Determining the effectiveness or impact of
CV in LMICs can be challenging. The quality of data and the con-
istency of clinician admission criteria is variable. For VE, case-
ontrol studies may be unreliable due to the lack of specificity of
he pneumonia case definition and the choice of community con-
rols may be biased. Drawing both cases and controls from pa-
ients that were hospitalised for the same condition, reduces bias
hat may otherwise occur from the association of vaccination and
ealth seeking behaviour [ 16 , 33 ]. A previous study found that hos-
ital controls had greater similarity of demographic characteristics
o pneumonia cases than community controls [34] . We describe a
ariant of a case-control study design using hospital-based controls
ho had pneumonia but were not hypoxic. Although observational
tudies have inherent issues regarding confounding, we used PS
nalysis to adjust for this by balancing covariates between expo-
ure groups. An advantage of the PS analysis is that it allows the
alance of covariates to be reviewed (e.g. using standardised differ-
nces) [ 35 , 36 ]. Achieving covariate balance strengthens the internal
alidity of our study and gives greater confidence that any effect
bserved may be due to the causal relationship between PCV13
nd protection from hypoxic pneumonia [35] . Furthermore, the PS
odel can be developed and checked before running the logistic
egression for estimating VE and thus avoids results influencing
ethodology [37] . However, the validity of PS analyses also relies
n a number of assumptions, including exchangeability (i.e. no un-
easured confounding), positivity (i.e. all children had a possibility
f being vaccinated), and stable unit treatment assumption (i.e. the
ffect of vaccination for one individual does not depend on another
erson’s vaccination status) [37] . Although we endeavoured to ful-
l the assumptions, it is possible that some assumptions were not
et. It is possible that some unmeasured confounders were not
ccounted for, which is a limitation of this study and all observa-
ional studies. However, our additional analysis of the control con-
ition, which demonstrated PCV13 was not effective against total
R. Weaver, C.D. Nguyen and J. Chan et al. / The Lancet Regional Health - Western Pacific 2 (2020) 10 0 014 7 
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 neumococcal carriage, as expected, provides reassurance for our
tudy design. 
There were also a number of additional limitations to our study.
lthough all patients admitted with ARIs were eligible for the
tudy, only patients who sought medical attention at Mahosot Hos-
ital were included. This is likely to limit inclusion to middle-
ncome families who live in the urban capital, which could affect
eneralisability of results to a wider population, whereby 66.9%
ive in rural areas and are poorer than urban dwellers [38] . Ef-
orts were made to follow up and collect clinical information and
CV13 status for all children. In our study, PCV13 status was de-
ermined based on parent-held records, and if that was not avail-
ble, vaccination was ascertained from health centre records where
ossible. Although these sources were preferred over parent recall,
hich has been found to be unreliable for determining immunisa-
ion status in other studies [39] , it is still possible that misclassi-
cation of vaccination status occurred. Additionally, children with
heeze were included in the analysis. The WHO criteria for pneu-
onia has been shown to have poorer sensitivity and specificity in
hildren with wheeze. However, both measures are improved with
he addition of fever in the case definition [40] . Furthermore, the
umber of children in our study with wheeze was similar between
roups. Finally, although this was a prospective study, undertaking
esearch in LMICs can be challenging and missing data still occur
ven with a prospective design. To address the missing values we
sed multiple imputation and found a 35% PCV13 VE and a high
evel of evidence for likely effect, providing further support of the
eracity of our findings. 
In conclusion, these results show PCV13 is effective against hy-
oxic pneumonia in an Asian setting. Considering the high bur-
en of pneumonia and limited access to treatment in LMIC set-
ings, PCV13 is likely to substantially reduce childhood mortality in
his region. These results provide a compelling argument to policy
akers for the continued use of PCV13 in the childhood immu-
isation program and for its introduction into other similar coun-
ries. Moreover, we have described a low-cost and simple single
ospital-based method for assessing PCV VE on pneumonia, which
ugments existing evaluation methods and advances implementa-
ion science methodology, especially for LMICs [41] . 
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